Effect of mood and anxiety disorders on health care utilization in multiple sclerosis.
Multiple sclerosis
epidemiology
health services
mood and anxiety disorders
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
pubmed:
14
10
2020
medline:
25
2
2023
entrez:
13
10
2020
Statut:
ppublish
Résumé
Little is known about the effects of changes in the presence or absence of psychiatric disorders on health care utilization in multiple sclerosis (MS). To evaluate the association between "active" mood and anxiety disorders (MAD) and health care utilization in MS. Using administrative data from Manitoba, Canada, we identified 4748 persons with MS and 24,154 persons without MS matched on sex, birth year, and region. Using multivariable general linear models, we evaluated the within-person and between-person effects of any "active" MAD on annual physician visits, hospital days, and number of drug classes dispensed in the following year. Annually, the MS cohort had an additional two physician visits, two drug classes, and nearly two more hospital days versus the matched cohort. Individuals with any MAD had more physician visits, had hospital days, and used more drug classes than individuals without a MAD. Within individuals, having an "active" MAD was associated with more utilization for all outcomes than not having an "active" MAD, but the magnitude of this effect was much smaller for visits and drugs than the between-person effect. Within individuals with MS, changes in MAD activity are associated with changes in health services use.
Sections du résumé
BACKGROUND
Little is known about the effects of changes in the presence or absence of psychiatric disorders on health care utilization in multiple sclerosis (MS).
OBJECTIVE
To evaluate the association between "active" mood and anxiety disorders (MAD) and health care utilization in MS.
METHODS
Using administrative data from Manitoba, Canada, we identified 4748 persons with MS and 24,154 persons without MS matched on sex, birth year, and region. Using multivariable general linear models, we evaluated the within-person and between-person effects of any "active" MAD on annual physician visits, hospital days, and number of drug classes dispensed in the following year.
RESULTS
Annually, the MS cohort had an additional two physician visits, two drug classes, and nearly two more hospital days versus the matched cohort. Individuals with any MAD had more physician visits, had hospital days, and used more drug classes than individuals without a MAD. Within individuals, having an "active" MAD was associated with more utilization for all outcomes than not having an "active" MAD, but the magnitude of this effect was much smaller for visits and drugs than the between-person effect.
CONCLUSION
Within individuals with MS, changes in MAD activity are associated with changes in health services use.
Identifiants
pubmed: 33045925
doi: 10.1177/1352458520963880
pmc: PMC8358559
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1411-1420Subventions
Organisme : CIHR
ID : THC-135234
Pays : Canada
Organisme : CIHR
ID : 333252
Pays : Canada
Références
CNS Spectr. 2006 Oct;11(10 Suppl 12):21-8
pubmed: 17008827
Mult Scler. 2005 Jun;11(3):328-37
pubmed: 15957516
Neurology. 2015 Jan 27;84(4):350-8
pubmed: 25540309
Neurology. 2015 Dec 1;85(22):1972-9
pubmed: 26519542
Can J Public Health. 2012 Jul 04;103(8 Suppl 2):S23-7
pubmed: 23618067
Med Care. 1991 May;29(5):452-72
pubmed: 1902278
Med Care. 2011 Oct;49(10):932-9
pubmed: 21478773
Health Serv Res. 2002 Oct;37(5):1345-64
pubmed: 12479500
Can J Neurol Sci. 2007 May;34(2):167-74
pubmed: 17598593
Clin Psychol Rev. 2007 Dec;27(8):959-85
pubmed: 17448579
BMC Res Notes. 2017 Nov 25;10(1):619
pubmed: 29178935
Eur Neuropsychopharmacol. 2012 Jan;22(1):36-43
pubmed: 21669514
Int J Psychiatry Med. 2002;32(2):167-78
pubmed: 12269597
Can J Neurol Sci. 2007 Aug;34(3):268-9
pubmed: 17803022
Neurology. 2016 Apr 12;86(15):1417-1424
pubmed: 26962068
Neurology. 2018 Apr 10;90(15):e1316-e1323
pubmed: 29523642
Health Serv Res. 1991 Apr;26(1):53-74
pubmed: 1901841
J Psychosom Res. 2017 Oct;101:17-23
pubmed: 28867419
Psychiatr Serv. 2019 Nov 1;70(11):1013-1019
pubmed: 31378194
Mult Scler. 2007 Jan;13(1):67-72
pubmed: 17294613
J Manag Care Pharm. 2010 Nov-Dec;16(9):703-12
pubmed: 21067256
Can J Neurol Sci. 2018 May;45(3):295-303
pubmed: 29557321
BMJ. 2017 Sep 13;358:j3927
pubmed: 28903922
Gen Hosp Psychiatry. 2018 Jul - Aug;53:65-72
pubmed: 29929117
J Drug Assess. 2019 May 24;8(1):97-103
pubmed: 31192030
Neuroepidemiology. 2018;51(1-2):1-10
pubmed: 29763935
BMC Neurol. 2013 Feb 06;13:16
pubmed: 23388102
Annu Rev Psychol. 2011;62:583-619
pubmed: 19575624
J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):658-664
pubmed: 27035372
BMC Neurol. 2014 Jun 03;14:117
pubmed: 24894415